NCT05323864

Brief Summary

Introduction: Currently, there is a lack of international guidelines or clinical recommendations for individuals with mental illnesses (i.e., bipolar disorder, posttraumatic stress disorder) going on high altitude sojourns. However, these guidelines would be important considering that mental illnesses are among the most common disorders worldwide and millions of people are hiking at high altitudes in the Alps, being granted easy access up to 3800m by cable cars. Before conceptualizing these guidelines, it seems necessary to study the physiological and psychological effects of ambient pressure changes leading to oxygen deficiency (hypoxia) in individuals with mental illnesses when being exposed to hypoxic conditions. The investigators hypothesize a shift towards negative affective responses and state anxiety as well as increased levels of neurotransmitter precursor amino acids (PHE/TYR and KYN/TRP) in individuals with mental illnesses when being exposed to hypoxic conditions. Methods and Analysis: The investigators plan to perform a double-blind randomized controlled trial in a safe laboratory environment by using a normobaric hypoxic chamber. Participants suffering from depression and anxiety symptoms will be included as well as age and sex-matched healthy controls. They will attend a six-hour exposure equivalent to 3800m of altitude as well as a six-hour exposure to sham hypoxic conditions. Recruited participants will be screened by the Beck Anxiety and Depression Inventory, the Symptom Checklist (SCL-90) as well as an interview assessment. Affective responses in state anxiety will be assessed before, and during each hour of exposure by using the Feeling Scale (FS), Felt Arousal Scale (FAS), Positive and Negative Affect Schedule (PANAS), State-Anxiety Inventory (STAI) and subjective mental stress levels (Visual Analogue Scale; VAS). Physiological parameters will be assessed by venous blood sampling, pulse oximetry and oxidative stress level measurement before entering the chamber, after three and six hours of exposure. Additionally, symptoms of acute mountain sickness will be assessed by the Lake Louise Score before, after three and six hours of exposure. Follow-up measurements are planned one and seven days after the chamber visit, consisting of venous blood sampling, the Beck Anxiety and Depression Inventory. A series of univariate analyses of covariance (ANCOVA) for repeated measures will be used to test the three-way (i.e. "group × condition × time") and two-way ("group × condition" and "group × time") interactions. Analyses will be adjusted for possible confounding, by adding age, sex, smoking, prior AMS, and medication status in the models as covariates. Ethics and dissemination: Ethical approval has been obtained from the ethics committee of the Medical University of Innsbruck (1250/2021).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
68

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 21, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 12, 2022

Completed
1 year until next milestone

Study Start

First participant enrolled

April 14, 2023

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

December 10, 2025

Status Verified

December 1, 2025

Enrollment Period

2.3 years

First QC Date

February 21, 2022

Last Update Submit

December 2, 2025

Conditions

Keywords

anxietydepressive symptomshigh altitude

Outcome Measures

Primary Outcomes (3)

  • Changes in affective responses

    Self-reported questionnaire to assess affective valence, perceived activation, positive and negative affect

    up to 6 hours, including 8 measurements, measuring before the start of intervention, every hour during the intervention, and after the end of intervention

  • Changes in state anxiety

    Self-reported questionnaires to assess state anxiety

    up to 6 hours, including 8 measurements, measuring before the start of intervention, every hour during the intervention, and after the end of intervention

  • Changes in subjective perception of stress

    Self-reported questionnaires to assess subjective perception of stress

    up to 6 hours, including 8 measurements, measuring before the start of intervention, every hour during the intervention, and after the end of intervention

Secondary Outcomes (4)

  • Changes in anxious-depressive symptoms

    10 days, including 3 measurements at baseline, day 1 and follow-up day 7

  • Changes in inflammatory parameters CRP

    8 days, including 4 measurements pre intervention, after 3 hours of intervention, at the end of intervention (6 hours), and at follow-up after 7 days

  • Changes in inflammatory parameters IL-6

    8 days, including 4 measurements pre intervention, after 3 hours of intervention, at the end of intervention (6 hours), and at follow-up after 7 days

  • Changes in oxidative stress

    6 hours, including 3 measurements, measuring pre intervention, after 3 hours of intervention, at the end of intervention (6 hours)

Study Arms (2)

Normobaric hypoxia

EXPERIMENTAL

Normobaric hypoxia equivalent to 3800m terrestrial altitude. The chamber located on the campus of the University of Innsbruck's Department of Sport Science. The chamber dimension is 5 x 3m.

Biological: Hypoxia

Sham hypoxia

SHAM COMPARATOR

The chamber located on the campus of the University of Innsbruck's Department of Sport Science. The chamber dimension is 5 x 3m.

Biological: Hypoxia

Interventions

HypoxiaBIOLOGICAL

Participants will be randomly assigned to start with the normobaric hypoxia condition or the sham hypoxia condition. They will swap to the other condition during the second visit, which will be executed at least 14 days after the first visit. Each sojourn will last for six hours and participants will reside in the chamber individually. During the six-hour stay, participants will be allowed to move freely within the chamber.

Normobaric hypoxiaSham hypoxia

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • sufficient command of the German language
  • no psychotic or cognitive disorders
  • patients suffering from anxious-depressive symptoms (meeting the cut off points of light-medium in the screening for anxiety and depression symptoms)

You may not qualify if:

  • pregnant or breastfeeding
  • permanent residence above 1000m
  • overnight stays at altitudes above 2500m in the previous month
  • exposure to 2500m or higher two weeks prior to the six-hour hypoxic exposure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Innsbruck, Department of Sport Science

Innsbruck, Tyrol, 6020, Austria

RECRUITING

MeSH Terms

Conditions

HypoxiaMental DisordersAnxiety DisordersDepressionAltitude Sickness

Condition Hierarchy (Ancestors)

Signs and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsBehavioral SymptomsBehaviorRespiration DisordersRespiratory Tract Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Model Details: A double-blind randomized controlled crossover trial with two groups of participants will be conducted. One group will be a group of psychiatric patients and the other group will be a group of healthy controls. The study will follow a crossover design with random allocation of condition order (i.e., normobaric hypoxia or sham hypoxia).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 21, 2022

First Posted

April 12, 2022

Study Start

April 14, 2023

Primary Completion

July 15, 2025

Study Completion

December 1, 2025

Last Updated

December 10, 2025

Record last verified: 2025-12

Locations